secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2026-01-26T23:59:59+00:00
Accession:  0001193125-26-021660
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 3.03, 5.03, 5.01, 5.02, 8.01, 5.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indivior completes U.S. Domestication; begins trading on Nasdaq as Delaware corp under INDV
--------------------------------------------------------------------------------

- Scheme of Arrangement effective Jan 23, 2026; Indivior U.S. becomes ultimate parent of Indivior U.K.
- Common stock starts trading on Nasdaq Jan 26, 2026 under ticker INDV; CUSIP 45579U109.
- New 2026 Omnibus Equity Plan authorizes 17.5M shares; non-employee director annual cash retainer $75k-$100k.
- Directors and executive officers of Indivior U.K. continue in same roles at Indivior U.S.
- Note Purchase Agreement amended to reflect Indivior U.S. as reporting entity; indemnification agreements adopted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000119312526021660/0001193125-26-021660-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000119312526021660/d87169d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-021660

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer